Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31


Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.

Moss CA, Cojocaru E, Hanwell J, Ward S, Xu W, van Zyl M, O'Leary L, de Bono JS, Banerji U, Kaye SB, Minchom A, George AJ, Lopez J, McVeigh TP.

Eur J Cancer. 2019 May 9;114:97-106. doi: 10.1016/j.ejca.2019.04.009. [Epub ahead of print]


Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.

Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, Zubairi I, Savulsky C, Reyderman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R.

Br J Cancer. 2019 Feb;120(4):379-386. doi: 10.1038/s41416-019-0377-x. Epub 2019 Jan 25.


T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.


Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study.

Geva R, Lopez J, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Pereira KMC, Perets R.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1092-1101. doi: 10.1007/s00259-018-4234-6. Epub 2018 Dec 13.


Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA.

Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15.


A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.

Ingles Garces AH, Ang JE, Ameratunga M, Chénard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U.

Eur J Cancer. 2018 Nov;104:32-38. doi: 10.1016/j.ejca.2018.08.019. Epub 2018 Oct 10.


To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.

Ameratunga M, Kipps E, Okines AFC, Lopez JS.

Clin Cancer Res. 2019 Jan 1;25(1):21-28. doi: 10.1158/1078-0432.CCR-18-1999. Epub 2018 Sep 17. Review.


Next Generation Cancer Vaccines-Make It Personal!

Terbuch A, Lopez J.

Vaccines (Basel). 2018 Aug 9;6(3). pii: E52. doi: 10.3390/vaccines6030052. Review.


Detection of circulating tumour cell clusters in human glioblastoma.

Krol I, Castro-Giner F, Maurer M, Gkountela S, Szczerba BM, Scherrer R, Coleman N, Carreira S, Bachmann F, Anderson S, Engelhardt M, Lane H, Evans TRJ, Plummer R, Kristeleit R, Lopez J, Aceto N.

Br J Cancer. 2018 Aug;119(4):487-491. doi: 10.1038/s41416-018-0186-7. Epub 2018 Aug 1.


Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.

Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.


Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.

Minchom A, Aversa C, Lopez J.

Ther Adv Med Oncol. 2018 Jul 13;10:1758835918786658. doi: 10.1177/1758835918786658. eCollection 2018. Review.


CNS cancer immunity cycle and strategies to target this for glioblastoma.

Ameratunga M, Coleman N, Welsh L, Saran F, Lopez J.

Oncotarget. 2018 Apr 27;9(32):22802-22816. doi: 10.18632/oncotarget.24896. eCollection 2018 Apr 27. Review.


Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Coleman N, Michalarea V, Alken S, Rihawi K, Lopez RP, Tunariu N, Petruckevitch A, Molife LR, Banerji U, De Bono JS, Welsh L, Saran F, Lopez J.

J Neurooncol. 2018 Aug;139(1):107-116. doi: 10.1007/s11060-018-2847-z. Epub 2018 Apr 10.


The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

McVeigh TP, Sundar R, Diamantis N, Kaye SB, Banerji U, Lopez JS, de Bono J, van der Graaf WTA, George AJ.

Eur J Cancer. 2018 May;95:20-29. doi: 10.1016/j.ejca.2018.02.028. Epub 2018 Mar 31.


Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.

Coleman N, Ameratunga M, Lopez J.

Clin Med Insights Oncol. 2018 Feb 26;12:1179554918759079. doi: 10.1177/1179554918759079. eCollection 2018. Review.


High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.

Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.


Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.

Ameratunga M, Chénard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J.

Eur J Cancer. 2018 Jan;89:56-63. doi: 10.1016/j.ejca.2017.11.012. Epub 2017 Dec 8.


Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.

Brown JS, Sundar R, Lopez J.

Br J Cancer. 2018 Feb 6;118(3):312-324. doi: 10.1038/bjc.2017.376. Epub 2017 Nov 9. Review.


The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations.

Collins DC, Chenard-Poirier M, Lopez JS.

Curr Cancer Drug Targets. 2018;18(4):355-364. doi: 10.2174/1568009617666170927114440.


Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC.

J Clin Oncol. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. Epub 2017 May 10.


Supplemental Content

Loading ...
Support Center